Covaxin neutralises double mutant strain: ICMR
New Delhi: Covaxin, which is a Made-in-India COVID-19 vaccine, is able to neutralise multiple variants of SARS-CoV-2 and effectively works against the double mutant strain as well, claimed the Indian Council of Medical Research (ICMR) on Wednesday.
Bharat Biotech's Covaxin has received Emergency Use Authorizations (EUAs) for treating COVID-19 infected patients in India and in many other nations.
"ICMR study shows #COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well. @MoHFW_INDIA
@DeptHealthRes
#IndiaFightsCOVID19 #LargestVaccineDrive," ICMR tweeted.
ICMR study shows #COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well. @MoHFW_INDIA @DeptHealthRes #IndiaFightsCOVID19 #LargestVaccineDrive pic.twitter.com/syv5T8eHuR
— ICMR (@ICMRDELHI) April 21, 2021
The ICMR made the revelation at a time when India is witnessing a massive surge in COVID-19 infection cases.
India witnessed a massive spike in COVID-19 deaths as 2023 people died due to the virus in the past 24 hours, as per Ministry of Health website.
Continuing to witness the spike in daily count, India also recorded 2,95,041 new cases during the same period.
The total death toll due to the virus now stands at 1,82,553.
There are 2157538 active cases in the country at present.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.